Sort
82,697 grants matching “vaccine development”
Phase II Trial of H7N9 Influenza Vaccines - VTEU
$832,511David Bernstein · Cincinnati Childrens Hosp Med Ctr · N01 · FY2014 · AI
HIV-1 vaccine design emphasizing bnAb targets on membrane Env liposomes
$832,487Michael B Zwick · Scripps Research Institute, The · R01 · FY2023 · AI
Malaria Pathogenesis and Human Immunity
$832,448Rick Fairhurst · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Regulatory Compliance
$832,398David Beasley · University Of Texas Med Br Galveston · UC7 · FY2013 · AI
A universal MHC-E-restricted T cell vaccine for HIV
$832,221Jonah B. Sacha · Oregon Health & Science University · R01 · FY2017 · AI
SEQUENCE AND POLYMORPHISM OF RHESUS MACAQUE MHC
$832,219Fred Hutchinson Cancer Research Center · R24 · FY2002 · RR
Expanded Phase II Trial of Carraguard for Prevention of HPV Infection
$832,203Mark H. Einstein · Albert Einstein College Of Medicine · R01 · FY2010 · CA
Deep Learning-based Protein Design of HIV-1 Env GP120 Core Immunogens for CD4 Binding Site Germline Targeting
$832,117Marie Pancera · Fred Hutchinson Cancer Center · R01 · FY2024 · AI
PROTECTIVE CD8 T CELL RESPONSES to TUBERCULOSIS
$832,076Samuel M Behar · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · AI
Species-transcending prevention of mosquito vector infection
$832,071D. Noah Sather · Seattle Children'S Hospital · R01 · FY2025 · AI
Inhibition of hepatitis C by RNA-based therapeutics
$831,879Somagenics, Inc. · R44 · FY2005 · AI
Genital Anaerobes, Inflammation and HIV Risk; Rakai
$831,536Ronald H Gray · Johns Hopkins University · R01 · FY2011 · AI
Impact of the COVID-19 Pandemic on Patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias
$831,392John Hsu · Massachusetts General Hospital · U01 · FY2022 · AG
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine
$831,383Matthias Johannes Schnell · Thomas Jefferson University · R01 · FY2017 · AI
Balancing epithelial cell resistance and resilience to respiratory viral infections
$831,352Jose Manuel Ordovas-Montanes · Boston Children'S Hospital · R01 · FY2025 · HL
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV Vectors
$831,245Louis J. Picker · Oregon Health & Science University · R01 · FY2014 · AI
Lysine Acetylation in N. gonorrhoeae Quorum Sensing and Biofilm Formation
$831,215Michael A. Apicella · University Of Iowa · R01 · FY2014 · AI
Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome
$831,115Eduardo Vilar Sanchez · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines
$830,585Nicole Bergman · Xdemics Corporation · R42 · FY2022 · TR
Targeting IgM Memory to Establish Protective B Cell Responses to HIV
$830,527James J Kobie · University Of Rochester · R01 · FY2018 · AI
Pathogenic determinants of the SIV envelope transmembrane cytoplasmic domain
$830,518James A Hoxie · University Of Pennsylvania · R01 · FY2011 · AI
Developing small molecule therapeutics for Ebola hemorrhagic fever virus
$830,518Arnab Basu · Microbiotix, Inc · R01 · FY2012 · AI
Papillomavirus Virion Proteins and Vaccines
$830,516Douglas R. Lowy · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Chromatin infrastructure of the Igh locus and its influence on VH gene usage
$830,460Amy L. Kenter · University Of Illinois At Chicago · R01 · FY2019 · AI
In vivo CRISPR engineering of B cells to produce anti-HIV broadly neutralizing antibodies using novel nanoparticles
$830,363Jennifer Eileen Adair · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · AI